Page 9 - Simulations Plus News Today

Simulations Plus (NASDAQ:SLP – Free Report) released its earnings results on Thursday. The technology company reported $0.20 earnings per share (EPS) for the quarter, missing the consensus estimate of $0.21 by ($0.01), MarketWatch Earnings reports. Simulations Plus had a return on equity of 6.17% and a net margin of 19.32%. During the same quarter last […]

Oppenheimer analyst Francois Brisebois reiterated an Outperform rating on Simulations Plus, Inc. (NASDAQ: SLP) with a 

Simulations Plus, Inc. (NASDAQ:SLP – Free Report)’s stock price gapped down prior to trading on Friday following a weaker than expected earnings announcement. The stock had previously closed at $41.29, but opened at $40.37. Simulations Plus shares last traded at $41.02, with a volume of 21,804 shares changing hands. The technology company reported $0.20 earnings […]

Oppenheimer analyst Francois Brisebois reiterated an Outperform rating on Simulations Plus, Inc. SLP with a price target of $67. Brisebois sees SLP as an…

Simulations Plus (SLP) delivered earnings and revenue surprises of -4.76% and 0.90%, respectively, for the quarter ended May 2023. Do the numbers hold clues to what lies ahead for the stock?

Simulations Plus SLP is set to give its latest quarterly earnings report on Thursday, 2023-07-06. Here's what investors need to know before the announcement.…

Firms focus on drug-modeling software.

Market Overview According to the DataM market research report, the Global Idiopathic Pulmonary Fibrosis Market size reached US$ 2,184.4 million in 2022